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Abstract
Background: Olprinone hydrochloride is a newly developed compound that selectively inhibits PDE type III and is
characterized by several properties, including positive inotropic effects, peripheral vasodilatory effects, and a bronchodilator
effect. In clinical settings, olprinone is commonly used to treat congestive cardiac failure, due to its inotropic and
vasodilating effects. The mechanism of these cardiac effects is attributed to increased cellular concentrations of cAMP. The
aim of the present study was to evaluate the pharmacological action of olprinone on the secondary damage in
experimental spinal cord injury (SCI) in mice.
Methodology/Principal Findings: Traumatic SCI is characterized by an immediate, irreversible loss of tissue at the lesion
site, as well as a secondary expansion of tissue damage over time. Although secondary injury should be preventable, no
effective treatment options currently exist for patients with SCI. Spinal cord trauma was induced in mice by the application
of vascular clips (force of 24 g) to the dura via a four-level T5–T8 laminectomy. SCI in mice resulted in severe trauma
characterized by edema, neutrophil infiltration, and production of inflammatory mediators, tissue damage, apoptosis, and
locomotor disturbance. Olprinone treatment (0.2 mg/kg, i.p.) 1 and 6 h after the SCI significantly reduced: (1) the degree of
spinal cord inflammation and tissue injury (histological score), (2) neutrophil infiltration (myeloperoxidase activity), (3)
nitrotyrosine formation, (4) pro-inflammatory cytokines, (5) NF-kB expression, (6) p-ERK1/2 and p38 expression and (7)
apoptosis (TUNEL staining, FAS ligand, Bax and Bcl-2 expression). Moreover, olprinone significantly ameliorated the recovery
of hind-limb function (evaluated by motor recovery score).
Conclusions/Significance: Taken together, our results clearly demonstrate that olprinone treatment reduces the
development of inflammation and tissue injury associated with spinal cord trauma.
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Introduction
Olprinone is a selective phosphodiesterase type III (PDE III)
inhibitor widely used to treat circulatory conditions. Olprinone is
clinically used for treatment of acute heart failure [1,2] or cerebral
ischemia [3]. Olprinone was originally developed as a cardiotonic
agent, having positive inotropic and vasodilator actions. It
improves myocardial mechanical efficiency [4] via elevation of
intracellular cyclic AMP (cAMP) levels in both cardiomyocytes
and vascular smooth muscle cells. It also increases myocardial
contractility and reduces vascular resistance, leading to an
improvement of hemodynamic status [5]. Moreover, olprinone
augments cerebral blood flow by its direct vasodilator effect on the
cerebral arteries. Olprinone inhibits vascular contractility by
decreasing cytosolic Ca
2+ levels and the Ca
2+ sensitivity of the
contractile elements: these effects may be mediated by an increase
in cAMP content [6]. Finally, olprinone inhibits both von
Willebrand factor mediated and fibrinogen mediated platelet
aggregation [7]. In addition, olprinone has anti-inflammatory
actions at therapeutic concentrations clinically used for heart
failure [8].
Spinal cord injury (SCI) is a highly debilitating pathology [9].
Although innovative medical care has improved patient outcome,
advances in pharmacotherapy for the purpose of limiting neuronal
injury and promoting regeneration have been limited. Traumatic
SCI causes severe and permanent functional deficits due to the
primary mechanical insult followed by secondary tissue degener-
ation which may take which may take place over a period of weeks
or even months [10]. A key mediator of this process is an acute
and robust inflammatory response which involves the synthesis
and release of chemo- and cytokines and a coordinated
recruitment of circulating leucocytes as well as microglia from
the CNS parenchyma [11,12,13,14].
A recent report indicates that increased intracellular cAMP
levels lead to reduced SCI [15]. Increased intracellular cAMP
levels also reduce ischemia/reperfusion (IR)-induced renal injury
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No reports have addressed the role for olprinone in pathophys-
iology of SCI. Interestingly, olprinone reduces the IR-induced
acute renal injury in rats through enhancement of cAMP,
inhibition of leukocyte activation [19], and decreasing elevated
concentrations of cytokine-induced neutrophil chemoattractant-1
in septic rats [20].
No reports have addressed a role for olprinone in pathophys-
iology of SCI.
In this study, the use of olprinone hydrochloride, a specific PDE
III inhibitor, allowed us to demonstrate that PDE III activation
plays a key role in the modulation of secondary injury in the spinal
cord. In particular, we evaluated for the first time the effects of
olprinone, determining 1) the extent of anatomical injury, 2) hind
limb motor function 10 days after injury, 3) concentrations of key
pro-inflammatory cytokines that are important mediators of
secondary injury within the spinal cord, (4) neutrophil infiltration,
(5) NF-kB expression, (6) MAP kinases expression, (7) nitrotyrosine
formation, (8) apoptosis as TUNEL staining, (9) the Bcl-2 family of
proteins, and (10) S100b expression.
The present manuscript is a study aimed at demonstrating that
olprinone administration after experimental SCI in mice inhibits
pathways leading to inflammation and apoptotic cell death and
has a positive effect on the neurological outcome. Considering that
initiation of inflammatory responses in CNS is related to activation
of MAPKs, especially ERK1/2 and p38 MAPK, and that their
activation would be a determinant for neuronal death or survival
on certain occasions, the pharmacological impact of olpirone on
spinal cord trauma is of interest to medical scientists.
Materials and Methods
Animals
Male adult CD1 mice (25–30 g, Harlan Nossan, Milan, Italy)
were used for all studies. Mice were housed in individual cages (5
for each group) and maintained under 12:12 light-dark cycle at
2161uC and 5065% humidity. The animals were acclimated to
their environment for 1 wk and had ad libitum access to tap water
and standard rodent standard diet. All animal experiments
complied with regulations in Italy (D.M. 116192), Europe (O.J.
of E.C. L 358/1 12/18/1986) and USA (Animal Welfare
Assurance No A5594-01, Department of Health and Human
Services, USA). All behavioral testing was conducted in compli-
ance with the NHI laboratory animal care guidelines and with
protocols approved by the Institutional Animal Care and Use
Committee (Council directive # 87-848, October 19, 1987,
Ministe `re de l’Agriculture et de la Fore ˆt, Service Ve ´te ´rinaire de la
Sante ´ et de la Protection Animale, permission # 92-256 to SC).
The study was approved by the University of Messina Review
Board for the care of animals.
Spinal cord injury
Mice were anaesthetized using chloral hydrate (400 mg/kg
body weight). We used the clip compression model described by
Rivlin and Tator [21] and produced SCI by extradural
compression of spinal cord section exposed via a four-level T5–
T8 laminectomy, in which the prominent spinous process of T5
was used as a surgical guide. With the aneurysm clip applicator
oriented in the bilateral direction, an aneurysm clip with a closing
force of 24 g was applied extradurally at T5–T8 level. The clip
was then rapidly released with the clip applicator, which caused
SC compression. In the injured groups, the cord was compressed
for 1 min. Following surgery, 1.0 cc of saline was administered
subcutaneously in order to replace the blood volume lost during
the surgery. During recovery from anesthesia, the mice were
placed on a warm heating pad and covered with a warm towel.
Food and water were provided to the mice ad libitum. During this
time period, the animals’ bladders were manually voided twice a
day until the mice were able to regain normal bladder function.
Sham injured animals were only subjected to laminectomy. Spinal
cord tissues were taken at 24 h following trauma. Tissue segments
contained the lesion (1 cm on each side of the lesion), in according
to counts of retrogradely labeled neurons at the origin of distinct
descending motor pathways and to morphometric assessments of
normal residual tissue at the injury epicenter, as previously
described by Joshi and Fehlings [22].
Experimental Design
Mice were randomized into 4 groups (N=40 animals/group).
Sham animals, subjected to the surgical procedure except that the
aneurysm clip was not applied, were treated intraperitoneally (i.p.)
with vehicle (saline) or olprinone (0.2 mg/kg) 1 h and 6 h after
surgical procedure. The remaining mice were subjected to SCI (as
described above) and treated with an ip. bolus of vehicle (saline) or
olprinone (0.2 mg/kg) 1 h and 6 h after SCI. The doses of
olprinone (0.2 mg/kg) used here were based on previous in vivo
studies [23,24] and in agreement with preliminary dose-response
study (0.05–0.2 mg/kg). In experiments on motor score, the
animals were treated with olprinone (0.2 mg/kg), 1 h and 6 h after
SCI and daily until day 9. Ten mice from each group were
sacrificed at different time points in order to collect samples for the
evaluation of different parameters. Olprinone hydrochloride
(SIGMA-ALDRICH) was dissolved in normal saline and admin-
istered ip.
Myeloperoxidase activity
Myeloperoxidase (MPO) activity, an indicator of polymorpho-
nuclear leukocyte (PMN) accumulation, was determined in the
spinal cord tissues as previously described [25] at 24 hours after
SCI. At the specified time following SCI, spinal cord tissues were
obtained and weighed, each piece homogenized in a solution
containing 0.5% (w/v) hexadecyltrimethyl-ammonium bromide
dissolved in 10 mM potassium phosphate buffer (pH 7) and
centrifuged for 30 min at 20,0006 ga t4 uC. An aliquot of the
supernatant was then allowed to react with a solution of 1.6 mM
tetramethylbenzidine and 0.1 mM H2O2. The rate of change in
absorbance was measured spectrophotometrically at 650 nm.
MPO activity was defined as the quantity of enzyme degrading
1 mmol of peroxide per min at 37uC and was expressed as units of
MPO/g wet tissue.
Immunohistochemical localization of P-selectin,
Intercellular Cell Adhesion Molecule (ICAM)-1, IL-1 b,
TNF-a, nitrotyrosine, S-100, PAR, Fas Ligand (FasL), Bax
and Bcl-2
Twenty-four hours after SCI, the tissues were fixed in 10%
(w/v) PBS-buffered formaldehyde and 8 mm sections were cut
from paraffin embedded tissues and mounted on positively
charged slides for immunohistochemical staining. After deparaffi-
nization, endogenous peroxidase was quenched with 0.3% (v/v)
hydrogen peroxide in 60% (v/v) methanol for 30 min. The
sections were permeabilized with 0.1% (w/v) Triton X-100 in PBS
for 20 min. Non-specific adsorption was minimized by incubating
the section in 2% (v/v) normal goat serum in PBS for 20 min.
Endogenous biotin or avidin binding sites were blocked by
sequential incubation for 15 min with biotin and avidin,
respectively. Sections were incubated overnight with anti-GFAP
Olprinone and SCI
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12170(Cell Signaling, 1:500), anti-P-selectin antibody (Pharmingen,
1:500 in PBS, v/v), anti-ICAM-1 antibody (Pharmingen,1:500,
in PBS, v/v), anti-nitrotyrosine rabbit polyclonal antibody
(Upstate, 1:500 in PBS, v/v), anti-PAR antibody (BioMol, 1:200
in PBS, v/v), anti-FasL antibody (Santa Cruz Biotechnology,
1:500 in PBS, v/v), anti-TNF-a ligand antibody (Santa Cruz
Biotechnology, 1:500 in PBS, v/v), anti-IL-1b ligand antibody
(Santa Cruz Biotechnology, 1:500 in PBS, v/v), anti-Bax antibody
(Santa Cruz Biotechnology, 1:500 in PBS, v/v) or with anti-Bcl-2
polyclonal antibody (Santa Cruz Biotechnology, 1:500 in PBS,
v/v) or with anti-S-100 polyclonal antibody (Santa Cruz
Biotechnology, 1:500 in PBS, v/v). Sections were washed several
times with PBS, incubated with a biotinylated goat anti-rabbit
secondary antibody and in avidin-biotin peroxidase complex
(Vectastatin, ABC elite kit, Vector Laboratories).
In order to confirm that the immunoreaction for the
nitrotyrosine was specific some sections were also incubated with
the primary antibody (anti-nitrotyrosine) in the presence of excess
nitrotyrosine (10 mM) to verify the binding specificity. To verify
the binding specificity for IL-1b, TNF-a, PAR, FasL, Bax and Bcl-
2, some sections were also incubated with only the primary
antibody (no secondary) or with only the secondary antibody (no
primary). In these situations no positive staining was found in the
sections indicating that the immunoreactions were positive in all
the experiments carried out.
Immunocytochemistry photographs (n=5) were assessed by
densitometry and corrected to the background signal. Background
settings were adjusted from examination of negative control
specimens. The assay was carried out by using Optilab Graftek
software on a Macintosh personal computer (CPU G3-266). All
the immunocytochemistry analysis was carried out without
knowledge of the treatments.
Terminal Deoxynucleotidyltransferase-Mediated UTP End
Labeling (TUNEL) Assay
TUNEL assay was conducted by using a TUNEL detection kit
according to the manufacturer’s instruction (Apotag, HRP kit
DBA, Milan, Italy). Briefly, sections were incubated with 15 mg/ml
proteinase K for 15 min at room temperature and then washed
with PBS. Endogenous peroxidase was inactivated by 3% H2O2
for 5 min at room temperature and then washed with PBS.
Sections were immersed in terminal deoxynucleotidyltransferase
(TdT) buffer containing deoxynucleotidyl transferase and biotiny-
lated dUTP in TdT buffer, incubated in a humid atmosphere at
37uC for 90 min, and then washed with PBS. The sections were
incubated at room temperature for 30 min with anti-horseradish
peroxidase-conjugated antibody, and the signals were visualized
with diaminobenzidine. The number of TUNEL positive cells/
high-power field was counted in 5 to 10 fields for each coded slide.
Western blot analysis for IkB-a, NF-kB p65, Bax, Bcl-2,
FasL, p-ERK1/2, and phospho-p38 (Thr180/Tyr182)
Cytosolic and nuclear extracts were prepared as previously
described [26] with slight modifications. Briefly, spinal cord tissues
from each mouse were suspended in extraction Buffer A
containing 0.2 mM PMSF, 0,15 mM pepstatin A, 20 mM leupep-
tin, 1 mM sodium orthovanadate, homogenized at the highest
setting for 2 min, and centrifuged at 1,0006g for 10 min at 4uC.
Supernatants represented the cytosolic fraction. The pellets,
containing enriched nuclei, were re-suspended in Buffer B
containing 1% Triton X-100, 150 mM NaCl, 10 mM TRIS-
HCl pH 7.4, 1 mM EGTA, 1 mM EDTA, 0,2 mM PMSF,
20 mm leupeptin, 0,2 mM sodium orthovanadate. After centrifu-
gation 30 min at 15,0006 ga t4 uC, the supernatants containing
the nuclear protein were stored at 280 for further analysis. The
levels of IkB-a, p-ERK1/2, phospho-p38 MAP Kinase, Fas-L,
Bax, and Bcl-2 were quantified in cytosolic fraction from spinal
cord tissue collected after 24 hours after SCI, while NF-kB p65
levels were quantified in nuclear fraction.
Forty micrograms of protein was dissolved in Laemmli’s sample
buffer, boiled for 5 min, and subjected to SDSPAGE (8% or 15%
polyacrylamide). The blot was performed by transferring proteins
from a slab gel to nitrocellulose membrane at 240mA for 40 min
at room temperature using TRANS-BLOTH SD Semy-dry
Transfer Cell (BIORAD). The filters were blocked with 1x PBS,
5% (w/v) non fat dried milk (PM) for 40 min at room temperature
and subsequently probed with specific Abs IkB-a (Santa Cruz
Biotechnology, 1:1000), or anti-Bax (1:500; Santa Cruz Biotech-
nology), or anti-Bcl-2 (1:500; Santa Cruz Biotechnology), or anti-
pERK1/2 (1:1000 Santa Cruz Biotechnology) or anti-NF-kB p65
(1:1000; Santa Cruz Biotechnology) or anti-FasL (1:200; Santa
Cruz Biotechnology, C-178, IgG) or anti-phospho-p38 MAP
Kinase (Thr180/Tyr182) (1:1000; Cell Signaling) in 1x PBS, 5%
w/v non fat dried milk, 0.1% Tween-20 (PMT) at 4uC, overnight.
Membranes were incubated with peroxidase-conjugated bovine
anti-mouse IgG secondary antibody or peroxidase-conjugated goat
anti-rabbit IgG (1:2000, Jackson ImmunoResearch, West Grove,
PA) for 1 h at room temperature.
To ascertain that blots were loaded with equal amounts of
proteic lysates, they were also incubated in the presence of the
antibody against a-tubulin (for cytosolic extract) or lamin A/C (for
nuclear extract) proteins (1:10,000 Sigma-Aldrich Corp.).
Signals were detected with enhanced chemiluminescence
detection system reagent according to manufacturer’s instructions
(SuperSignal West Pico Chemiluminescent Substrate, Pierce). The
relative expression of the protein bands of IkB-a (,37 kDa),
NF-kB p65 (65 kDa), Bax (,23 kDa), Bcl-2 (,26 kDa), FasL
(,40 kDa), phospho-p38 MAP Kinase (43 kDa), was quantified
by densitometry with Image Quant TL software (GE Healthcare)
and standardized for densitometry analysis to housekeeping gene
levels. The dual-phosphorylated form of ERK (p-ERK) antibody
identified two bands of approximately 44 and 42 kDa (corre-
sponding to p-ERK1 and p-ERK2, respectively).
Images of blot signals (8 bit/600 dpi resolution) were imported
to analysis software (Image Quant TL, v2003). A preparation of
commercially available molecular weight markers (Precision Plus
Protein Kaleidoscope standards, BIO-RAD) consisting of proteins
of molecular weight 10 to 250 kDa was used to define molecular
weight positions and as reference concentrations for each
molecular weight.
Light microscopy
Spinal cord tissues were taken at 24 h following trauma. Tissue
segments containing the lesion (1 cm on each side of the lesion)
were paraffin embedded and cut into 5-mm-thick sections. Tissue
sections (thickness 5 mm) were deparaffinized with xylene, stained
with Haematoxylin/Eosin (H&E), and studied using light
microscopy (Dialux 22 Leitz).
The segments of each spinal cord were evaluated by an
experienced histopathologist. Damaged neurons were counted and
the histopathologic changes of the gray matter were scored on a 6-
point scale [27]: 0, no lesion observed, 1, gray matter contained 1
to 5 eosinophilic neurons; 2, gray matter contained 5 to 10
eosinophilic neurons; 3, gray matter contained more than 10
eosinophilic neurons; 4, small infarction (less than one third of the
gray matter area); 5, moderate infarction; (one third to one half of
the gray matter area); 6, large infarction (more than half of the
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cord were averaged to give a final score for individual mice. All the
histological studies were performed in a blinded fashion.
ELISA measurement of TNF-a and IL-1b
For the measurement of cytokines levels, a 1 cm sample
containing the lesion site (or comparable region of sham operated
animals) was rapidly dissected and homogenized in 1 ml PBS
containing protease inhibitors (Complete protease inhibitor
tablets, Roche). TNF-a and IL-1b levels were assayed using
DuoSet ELISA Development System (R&D Systems). All assays
were carried out in duplicate using recommended buffers, diluents
and substrates. Absorbency was determined using a microplate
reader at 450 nm (Thermo Scientific, Multiskan FC Microplate
Photometer). The intra-assay coefficient of variations for both
assays was less than 10%. The concentration of the cytokines in
the tissue was mentioned as pg/100 mg wet tissue.
Quantification of BMS Score
The BMS locomotor rating scale analyzed seven locomotor
categories. In our experiments, the motor function of mice
subjected to compression trauma was assessed once a day for 10
days after injury. Recovery from motor disturbance was graded
using the Basso Mouse Scale [28].
Materials
Olprinone hydrochloride was obtained from SIGMA-AL-
DRICH (CAS Number: 119615-63-3). All compounds were from
Sigma-Aldrich Company Ltd. (Milan, Italy). All other chemicals
were of the highest commercial grade available. All stock solutions
were prepared in non-pyrogenic saline (0.9% NaCl; Baxter, Italy,
UK).
Statistical evaluation
All values in the figures and text are expressed as mean 6
standard error of the mean (SEM) of N observations. For the in
vivo studies N represents the number of animals studied. In the
experiments involving histology or immunohistochemistry, the
figures shown are representative of at least three experiments
performed on different experimental days. The results were
analyzed by one-way ANOVA followed by a Bonferroni post-hoc
test for multiple comparisons. A p-value of less than 0.05 was
considered significant. BMS scale data were analyzed by the
Mann-Whitney test and considered significant when p- value was
,0.05.
Results
Olprinone reduces the severity of spinal cord trauma
The severity of the trauma at the level of the perilesional area
assessed as the presence of edema as well as alteration of the white
matter (Figure 1B and see histological score D), was evaluated at
24 h after injury. A significant damage to the spinal cord was
observed in the spinal cord tissue from SCI mice when compared
with sham-operated mice (1B). Notably, a significant protection
against the spinal cord injury was observed in injured mice treated
with olprinone 0.2 mg/kg (Figure 1C and see histological score D).
The dose of olprinone (0.2 mg/kg) used here were based on
preliminary dose-response study (0.05–0.2 mg/kg), showing a
significant protective effect of olprinone only at highest dose. In
order to evaluate if histological damage to the spinal cord was
associated with a loss of motor function, the modified BMS hind
limb locomotor rating scale score was evaluated. While motor
function was only slightly impaired in sham mice, mice subjected
to SCI had significant deficits in hind limb movement (Figure 1E).
Olprinone treatment ameliorated the functional deficits induced
by SCI (Figure 1E).
Olprinone reduces the activation of astrocytes after SCI
The cellular changes occurring in the perilesioned zone
(namely, at the boundary between the core necrotic area and
the penumbra zone) were evaluated by the expression of specific
glial/precursor cell markers. In line with previous literature data
[29], the characterization of spinal cord sections revealed
increased astrogliosis (GFAP
+ cells) in the perilesioned area from
SCI animals in comparison to sham-operated animals (Figure 2B).
On the contrary, significant less GFAP positive cells were found in
the spinal cord tissues after SCI collected from mice which have
been treated with olprinone (Figure 2C).
Effects of olprinone on neutrophil infiltration and protein
family of Cell Adhesion Molecules
The abovementioned histological pattern of spinal cord injury
appeared to be correlated with the influx of leukocytes into the
spinal cord. Therefore, we investigated the effect of olprinone on
the neutrophil infiltration by measuring tissue MPO activity. MPO
activity was significantly elevated in the spinal cord at 24 h after
injury in mice subjected to SCI when compared with sham-
operated mice (Figure 3A). Treatment with olprinone attenuated
neutrophil infiltration into the spinal cord at 24 h after injury
(Figure 3A). Moreover, at 24 h after SCI, a positive immunohis-
tochemical staining for ICAM-1 (Figure 3C; 6.5060.1, p,vs.
Sham, n=) and for P-selectin (Figure 3F; 5.5060.09, p,vs. Sham,
n=) was found in sections of spinal cord tissues compared to
sham-operated mice. The positive immunostaining for ICAM-1
(Figure 3D; 0.1760.09 vs. 6.5060.1, p, vs. SCI, n=) and for P-
selectin (Figure 3G; 0.2060.1 vs. 5.5060.09, p, vs. SCI, n=) was
significantly decreased in sections from mice treated with
olprinone (0,2 mg/kg).
Olprinone modulate the expression of TNF-a and IL-1b
after SCI
To test whether olprinone may modulate the inflammatory
process, we analyzed the spinal cord tissue levels of pro-
inflammatory cytokines. A substantial increase in TNF-a and IL-
1b production was found in spinal cord tissues samples collected
from SCI mice 24 hours after SCI (Figure 4A and B, respectively).
Spinal cord levels of TNF-a and IL-1b were significantly
attenuated by the intraperitoneal injection of olprinone
(Figure 4A and B, respectively). In addition, spinal cord sections
were also taken at 24 h after SCI to determine the expression of
TNF-a and IL-1-b by immunohistological staining. There was no
staining for TNF-a and IL-1-b in spinal cord obtained from the
sham mice (Figure 4 C and F, respectively). A substantial increase
in TNF-a (Figure 4D) and IL-1-b (Figure 4G) expression was
found in inflammatory cells as well as in nuclei of Schwann cells in
the white and gray matter of the spinal cord tissues collected from
SCI mice 24 hours after SCI. Spinal cord expression of TNF-a
(Figure 4E) and IL-1-b (Figure 4H) were significantly attenuated in
olprinone treated-SCI mice in comparison to SCI animals.
Effects of olprinone on nitrotyrosine formation, and PAR
formation after SCI
Twenty-four hours after SCI, nitrotyrosine, a specific marker of
nitrosative stress, was measured by immunohistochemical analysis
in the spinal cord sections to determine the localization of
‘‘peroxynitrite formation’’ and/or other nitrogen derivatives produced
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stain for nitrotyrosine (Figure 5A), whereas spinal cord sections
obtained from SCI mice exhibited positive staining for nitrotyr-
osine (Figure 5B; 6.8060.13, p,0.01 vs. Sham, n=5). The
positive staining was mainly localized in inflammatory cells as well
as in nuclei of Schwann cells in the white and gray matter of the
spinal cord tissues. Olprinone treatment reduced the degree of
positive staining for nitrotyrosine (Figure 5C, 0.1060.07 vs.
6.8060.13, p,0.01 vs. SCI, n=5) in the spinal cord.
In our study, immunohistochemistry for PAR, as an indicator of
in vivo PARP activation, revealed the occurrence of positive
staining for PAR localized in nuclei of Schwann cells in the white
and gray matter of the spinal cord tissues from mice subjected to
SCI (Figure 5E, 6.5060.14, p, vs. Sham, n=). Olprinone
treatment reduced the degree of positive staining for PAR
(Figure 5F, 0.2960.09 vs. 6.5060.14, p,0.01 vs. SCI, n=5) in
the spinal cord.
Effect of olprinone on IkB-a degradation, and NF-kB p65
activation
We evaluated the degradation of the inhibitor of NF-kB, IkB-a,
and nuclear NF-kB p65 by Western Blot analysis to investigate the
cellular mechanisms by which treatment with olprinone may
attenuate the development of SCI.
A basal level of IkB-a was detected in the spinal cord from sham-
operated animals, whereas IkB-a levelswere substantially reduced in
SCI mice (Figure 6A; 5.7760.8 vs. 11.8061.01, p,0.01 vs. Sham;
n=5). Olprinone administration prevented the SCI-induced IkB-a
degradation (Figure 6A; 9.7960.5 vs. 5.860.9, p,0.05 vs. SCI;
Figure 1. Effect of olprinone treatment on histological alterations of the spinal cord tissue 24 h after injury. A significant damage to
the spinal cord at the perilesional area was assessed by the presence of edema as well as alteration of the white matter 24 h after injury (B). Notably,
a significant protection from the SCI was observed in the tissue collected from olprinone treatment (0,2 mg/kg) treated mice (C). The histological
score (D) was made by an independent observer and showed also a dose-response study with 0,05-0,1-0,2 mg/kg olprinone. wm: White matter; gm:
gray matter. This figure is representative of at least 3 experiments performed on different experimental days. The degree of motor disturbance
(E) was assessed every day until 10 days after SCI using the Basso Mouse Scale. Treatment with olprinone (0,2 mg/kg) reduces the motor disturbance
after SCI. Values shown are mean 6 s.e. mean of 10 mice for each group. up,0.01 vs. SCI.
doi:10.1371/journal.pone.0012170.g001
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spinal cord tissue were also significantly increased at 24 h after SCI
compared to the sham-operated mice (Figure 6B; 3.6660.2 vs.
0.1060.04, p,0.001 vs. Sham; n=5). Olprinone treatment
significantly reduced the levels of NF-kB p65 as shown in
Figure 6B (1.4960.41 vs. 3.6760.2, p,0.01 vs. SCI; n=5).
Olprinone modulates the induction of phospho-ERK and
phospho-P38 after SCI
We also evaluated the level of phosphorylated ERK1/2 which
results in expression of pro-inflammatory genes mediating the
inflammatory responses characteristic of SCI. The activation of
MAPK pathways in particular the phosphorylation of ERK1/2
expression was investigated by Western blot in spinal cord
homogenates at 24 h after SCI. A significant increase in
pERK1/2 levels were observed in SCI mice (Figure 7A;
6.7860.7 vs. 1.3360.2, p,0.01 vs. Sham; n=5). The treatment
of mice with olprinone significantly reduced the level of pERK1/2
(Figure 7A; 3.2163.2 vs. 6.7860.7, p,0.01 vs. SCI; n=5). In
addition, at 24 h after SCI, the activation of phospho-P38 in spinal
cord homogenates was investigated by Western blot. A significant
increase in phospho-P38 (Figure 7B; 5.9760.6 vs. 0.3660.1,
p,0.01 vs. Sham; n=5) levels were observed in the spinal cord
from mice subjected to SCI. On the contrary, olprinone treatment
prevented the SCI-induced (Figure 7B; 2.4060.3 vs 5.9760.6,
p,0.01 vs. SCI; n=5) expression of these kinases.
Effects of olprinone on FasL expression and on S100b
Immunoreactive profiles in spinal cord after injury
To investigate the induction of apoptotic pathways triggered by
Fas-FasL binding, immunohistological staining for FasL in the
spinal cord was also determined 24 h after injury. Spinal cord
sections from sham-operated mice did not stain for FasL
(Figure 8A), whereas spinal cord sections obtained from SCI mice
exhibited positive staining for FasL (Figure 8B, 5.0060.1, p,0.01
vs. Sham, n=5) mainly localized in inflammatory cells as well as in
nuclei of Schwann cells. Olprinone treatment reduced the degree
of positive staining for FasL in the spinal cord (Figure 8C,
0.2060.07 vs 5.0060.1, p,0.01 vs. SCI, n=5). Similarly, a
significant increase in FasL (Figure 8G; 6.2860.9 vs. 0.2860.1,
p,0.01 vs. Sham n=5) levels were observed in the spinal cord
from mice subjected to SCI by Western blot. On the contrary,
olprinone treatment prevented the SCI-induced FasL (Figure 8G;
2.5860.7 vs. 6.2860.9, p,0.01 vs. SCI n=5) expression.
To characterize the changes in S100b in paracrine trophic
mechanisms in the lesioned spinal cord, S100b immunoreactive
quiescent astrocytes with a small size and thin processes were seen
distributed throughout the white and gray matters of the sham-
operated mice (Figure 8D). SCI in mice increased the number of
S100b immunoreactive astrocytes with a large cytoplasm and thick
processes, in the white and grey matters of the spinal cord at
caudal levels adjacent to the injury (Figure 8E, 4.860.2). This
number of S100b immunoreactive astrocytes is significantly
reduced in the spinal cord obtained from olprinone-treated SCI
mice (Figure 8F, 0.1860.06 vs. 4.860.2, p,0.01 vs. SCI n=5).
Effects of olprinone on apoptosis in spinal cord after
injury
To test whether spinal cord damage was associated to cell death
by apoptosis, we measured TUNEL-like staining in the perilesional
spinal cord tissue. Almost no apoptotic cells were detected in the
spinal cord from sham-operated mice (Figure 9A). At 24 h after the
trauma, tissues from SCI mice demonstrated a marked appearance
of dark brown apoptotic cells and intercellular apoptotic fragments
Figure 2. Effect of olprinone treatment on astrogliosis in the spinal cord tissue 24 h after injury. No positive staining for GFAP were
observed in the spinal cord tissues collected from sham-operated mice (a). A significant presence of GFAP positive cells was found in the spinal cord,
from SCI operated mice at the perilesional area 24 h after injury (b). Notably, a significant reduction of GFAP positive cells was observed in the tissue
collected from olprinone-treated mice (c). This figure is representative of at least 3 experiments performed on different experimental days.
doi:10.1371/journal.pone.0012170.g002
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PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12170(Figure 9B B1, see positive cell count D). In contrast, tissues obtained
from mice treated with olprinone demonstrated no apoptotic cells or
fragments (Figure 9C, see positive cell count D).
Western blot analysis and immunohistochemistry for Bax
and Bcl-2
At 24 h after SCI, the appearance of proteic effectors of
canonical mitochondrial apoptosis, such as pro-apoptotic (Bax)
and anti-apoptotic (Bcl-2) proteins, was investigated by Western
blot. The balance of Bax levels were appreciably increased in the
spinal cord from mice subjected to SCI (Figure 10A; 3.3660.8 vs.
0.1460.04, p,0.01 vs. Sham, n=6). On the contrary, olprinone
treatment prevented the SCI-induced Bax expression (Figure 10A;
0.3060.2 vs. 3.3660.8, p,0.01 vs. SCI n=6).
By Western blot analysis Bcl-2 expression was also analyzed in
homogenates from spinal cord of each mouse. A basal level of Bcl-2
Figure 4. Effects of olprinone on pro-inflammatory cytokines. By ELISA measurement, TNF-a (A) and IL-1b (B) levels were significantly
increased in the spinal cord from SCI mice. On the contrary, olprinone treatment (0,2 mg/kg 1 h and 6 h after SCI induction) prevented the SCI-
induced levels of these cytokines (A and B). In addition, spinal cord sections were processed at 24 h after SCI to determine the immunohistological
staining for TNF-a and IL-1b expression. A substantial increase in TNF-a (D) and IL-1b (G) expression was found in inflammatory cells, in wm and gm
of the spinal cord tissues from SCI mice. Tissue expression of TNF-a (E) and IL-1b (H) were significantly attenuated in olprinone -treated mice in
comparison to SCI animals. The assay was carried out by using Optilab Graftek software on a Macintosh personal computer (CPU G3-266).
doi:10.1371/journal.pone.0012170.g004
Figure 3. Effects of olprinone on MPO activity and superfamily of adhesion molecules. Following the injury, MPO activity in spinal cord
from SCI mice was significantly increased at 24 h after the damage in comparison to sham groups (A). In addition, at 24 h after SCI, a positive
immunohistochemical staining for ICAM-1 (C) and for P-selectin (F) was found in spinal cord sections compared to sham-operated mice (B and E,
respectively). The positive immunostaining for ICAM-1 and for P-selectin was significantly decreased in sections from mice treated with olprinone
(0,2 mg/kg) (D and G, respectively).
doi:10.1371/journal.pone.0012170.g003
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(Figure 10B). Twenty-four hours after SCI, the Bcl-2 expression was
significantly reduced in spinal cord from SCI mice (Figure 10B;
6.5761.4 vs. 14.6261.4, p,0.01 vs. Sham n=6). Treatment of
mice with olprinone significantly blunted the SCI-induced inhibi-
tion of anti-apoptotic protein expression (Figure 10B; 15.4161.6 vs.
6.5761.4 p,0.01 vs. SCI n=6).
Moreover, samples of spinal cord tissue taken at 24 h after SCI
were also processed for immunohistological staining for Bax and
Bcl-2. Spinal cord sections from sham-operated mice did not stain
for Bax (Figure 11A) whereas spinal cord sections obtained from
SCI mice exhibited a positive staining for Bax (Figure 11B,
4.9560.1, p,0.01 vs. Sham, n=5). Olprinone treatment reduced
the degree of positive staining for Bax in the spinal cord of mice
subjected to SCI (Figure 11C, 0.1460.07 vs. 4.9560.1, p,0.01 vs.
SCI, n=5). In addition, spinal cord sections from sham-operated
mice demonstrated Bcl-2 positive staining (Figure 11D) while in
SCI mice the staining significantly reduced (Figure 11E,
0.2060.08 vs. 6.4060.06, p,0.01 vs. Sham, n=5). Olprinone
treatment attenuated the loss of positive staining for Bcl-2 in the
spinal cord from SCI- subjected mice (Figure 11F, 5.5060.1 vs.
0.2060.08, p,0.01 vs. SCI, n=5).
Discussion
Olprinone, a specific PDE III inhibitor, has been found to have
inotropic and peripheral vasodilatory effects [4,30]. It is well
known that the substrate specificity of PDE III is cAMP . cGMP;
therefore, PDE III inhibitors will increase the intracellular cAMP
concentration [9–11]. Downstream effector proteins of cAMP and
cGMP include PKA, PKG, cyclic nucleotide-gated ion channels,
and cAMP-regulated guanine nucleotide exchanger factors [31].
Figure 5. Effects of olprinone on nitrotyrosine formation and PAR. Sections obtained from SCI animals demonstrate positive staining for
nitrotyrosine (B) mainly localized in inflammatory, in Schwann cells in the white and gray matter. Olprinone treatment (0,2 mg/kg, 1 and 6 h after SCI
induction) reduced the degree of positive staining for nitrotyrosine (C) in the spinal cord. PAR expression, as an indicator of in vivo PARP activation,
revealed the occurrence of positive staining localized in nuclei of Schwann cells in the white and gray matter of the spinal cord tissues from mice
subjected to SCI (E). Olprinone treatment reduced the degree of positive staining for PAR (F) in the spinal cord. Figures are representative of at least3
experiments performed on different experimental days.
doi:10.1371/journal.pone.0012170.g005
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detected in the spinal cord from sham-operated animals, whereas IkB-a levels were substantially reduced in SCI mice. Olprinone treatment (0,2 mg/kg,
1 and 6 h after SCI induction) prevented the SCI-induced IkB-a degradation (A). In addition, SCI caused a significant increase in nuclear NF-kBp 6 5
comparedto thesham-operated mice (B). Olprinonetreatment significantly reducedNF-kB p65 expression as shownin B. a-tubulin andlamin A/Cwere
used as internal control for cytosolic and nuclear extract, respectively. A representative blot of lysates obtained from each group is shown. The relative
expression of the protein bands from three separated experiments was standardized for densitometric analysis to housekeeping genes.
doi:10.1371/journal.pone.0012170.g006
Figure 7. Effect of olprinone on activated kinases. The spinal cord extract were immunoblotted for the dual-phosphorylated form of ERK and
for phosphor-P38. pERK1/2 is upregulated in injured mice as compared to sham-operated mice (A). Spinal cord levels of pERK1/2 were significantly
attenuated in olprinone (0,2 mg/kg)-SCI treated mice in comparison to SCI animals (A). Similarly, the treatment with olprinone significantly reduced
the SCI-induced increase of the expression of phospho-P38 (B).
doi:10.1371/journal.pone.0012170.g007
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with olprinone in mice exerts a protective effect against the
pathological changes caused by SCI. Thus, we propose that PDE
III contributes to the pathophisiology of SCI. The mechanism of
action of the PDE inhibitors has been partially elucidated and is
thought to involve the enhancement of anti-inflammatory
cytokines and the suppression of pro-inflammatory cytokines.
cAMP-elevating agents are known to modulate cytokine produc-
tion. Eigler et al. reported that cAMP elevating agents modulate
immune cells by decreasing TNF-a and increasing IL-10 through
PKA [32]. IL-10 has profound autoregulatory and primarily
negative effects on macrophage activation [33] and macrophages
are believed to play a key role during the progression of
inflammation. Macrophages, as target cells, have the highest level
of PDE III compared to several cell types, including lymphocytes,
monocytes, and endothelial cells. Macrophages perform important
functions in the removal of myelin debris and the products of
neuronal degeneration following trauma, infection, or autoim-
mune reactions within the neuronal systems. However, the true
mechanism of PDE inhibitors has not yet been fully elucidated.
Much of the damage that occurs in the spinal cord following
traumatic injury is due to the secondary effects of glutamate
Figure 8. Effect of olprinone on immunohistochemical localization and expression of Fas-ligand. At 24 hr after SCI a substantial increase
in Fas-ligand expression (B) was found in inflammatory cells, in nuclei of Schwann cells in wm and gm of the spinal cord tissues. Spinal cord Fas-
ligand was significantly attenuated in olprinone-SCI treated mice in comparison to SCI animals (C). Moreover, SCI increased the number of S100b
immunoreactive astrocytes in the white and grey matters of the spinal cord at caudal levels adjacent to the injury (E). This number of S100b
immunoreactive astrocytes is significantly reduced in the spinal cord obtained from oprinone-treated SCI mice (F). Densitometry analysis of
immunocytochemistry photographs (n=5 photos from each sample collected from all mice in each experimental group) for Fas-ligand and S100b
from spinal cord tissues was assessed. Similarly, at 24 h after SCI, the expression of Fas-ligand in the spinal cord homogenates was investigated by
Western blot. A significant increased Fas-ligand (H) expression was observed in the spinal cord from mice subjected to SCI. On the contrary, olprinone
treatment prevented the SCI-induced Fas-ligand (H) expression. This figure is representative of at least 3 experiments performed on different
experimental days. wm: White matter; gm: gray matter.
doi:10.1371/journal.pone.0012170.g008
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2+ overload, and oxidative stress, three mecha-
nisms that take part in a spiraling interactive cascade ending in
neuronal dysfunction and death [34,35,36,37,38,39,40].
SCI incidence and prevalence are not precisely known
depending on the country. It is difficult to act on primary lesions,
thus there is a critical need to develop new pharmacologic
approaches for treatment of SCI.
Several lines of evidence support the potential neuroprotective
effects of olprinone [41,42].
PKA activation, caused by cAMP, is reported to lead to
augmentation of p38 MAPK activity through protein tyrosine
phosphatase [5]. Moreover, Xu and colleagues have clearly
demonstrated in vivo an enhanced activation of ERK1/2 and p38
MAPK in the injured spinal cord after traumatic SCI persists at
least for 24 h after injury [43]. Moreover, ERK1/2 and p38
MAPK signaling pathways have been found to be involved in
microglia/macrophage activation [44,45,46]. Recently, it has been
demonstrated that the elevation of cell cAMP levels inhibits NF-kB
activation by targeting p38 MAPK [47]. Thus, the activity of
olprinone on the cAMP levels might account for its effect on
NF-kB activation, since have been showed that cAMP also
activates PKA, which inhibits NF-kB [48].
NF-kB plays a central role in the regulation of many genes
responsible for the generation of mediators or proteins in
inflammation. These include the genes for TNF-a, IL-1b, iNOS
and COX-2 [49]. In this regard, it has been well demonstrated
that in SCI the expression of proinflammatory cytokines (TNF-a
and IL-1b) at the site of injury regulates the precise cellular events
after SCI [50,51]. We have clearly confirmed a significant increase
in TNF-a and IL-1b in SCI. On the contrary, no significant
expression of TNF-a and IL-1b was observed in the spinal cord
sections obtained from SCI-operated mice which received
olprinone confirming that PDE III pathway play an important
role in the regulation of proinflammatory cytokines. This
observation is in agreement with previous studies in which have
been demonstrated that olprinone treatment reduced the gener-
ation and release of proinfiammatory cytokines [52,53,54].
Olprinone may thus have a unique therapeutic profile, capably
Figure 9. Effects of olprinone on TUNEL-like staining in the perilesional spinal cord tissue and S100b expression. At 24 h after the
trauma, SCI mice demonstrated a marked appearance of dark brown apoptotic cells and intercellular apoptotic fragments (B and B1). In contrast,
tissues obtained from mice treated with olprinone (0,2 mg/kg) demonstrated no apoptotic cells or fragments (C). The number of TUNEL positive
cells/high-power field was counted in 5 to 10 fields for each coded slide (D). Figure is representative of at least 3 experiments performed on different
experimental days.
doi:10.1371/journal.pone.0012170.g009
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cascades.
Furthermore, we observed that treatment with olprinone
abolished the expression of P-selectin and ICAM-1. These results
demonstrate that inhibition of the PDEIII pathway may interrupt
the interaction neutrophils and endothelial cells both at the early
rolling phase mediated by P-selectin and at the late firm adhesion
phase mediated by ICAM. The absence of an increased expression
of the adhesion molecule in spinal cord tissue from injured mice
treated with olprinone correlated with the reduction of leukocyte
infiltration and with the attenuation of the spinal cord tissue
damage, suggesting that it not only reduced the local inflammatory
response, but also reduced leukocyte infiltration from the
periphery. As neutrophils release ROS, chemokines and other
key determinants of secondary tissue damage [55], the invasion of
neutrophils after SCI is closely linked to the severity of secondary
spinal cord injury.
Therefore, various studies have demonstrated that PARP
activation after single DNA strand breakage induced by ROS
plays an important role in the process of SCI [56,57]. In this study
we confirm the increase in PAR formation in the spinal cord from
SCI mice and show that olprinone treatment attenuates PARP
activation.
Secondary degeneration at the site of SCI appear to be due in
part to apoptosis [58]. After SCI, typical post-traumatic necrosis
occurred, but in addition apoptotic cells were found from 6 hours
to 3 weeks after injury, especially in the spinal white matter,
involving oligodendrocytes and microglia [59].
There is broad consensus in the scientific literature that SCI
induces the extrinsic apoptosis pathway via Fas activation in vitro
and in vivo [60,61,62,63,64]. Initiation of apoptosis provides that
mitochondria and caspases engage in a self-amplifying pathway of
mutual activation. Caspases might have a dual function in the
apoptotic process: first, as signal-transduction molecules that act as
facultative inducers of mitochondrial membrane changes, and,
second, as processing enzymes that orchestrate the apoptotic
phenotype [65,66]. SCI leads to increased expression of Fas and
FasL, which results in the continued activation of microglia and
the inflammatory response, inducing a cascade of apoptotic cell
death and extension of the initial damage [67].
Neuronal and oligodendroglial apoptosis contributes to demy-
elination and Wallerian degeneration, and thereby affects
neuronal function and survival after SCI. In agreement with
these findings, we have demonstrated a significant increase in
TUNEL-positive cells in the perilesional zone following SCI.
These data provide evidence that the functional neurological
deficits after SCI are associated with demyelination and the loss of
neurons and oligodendrocytes.
The ability of the Fas–FasL system to activate apoptotic
pathways raises questions about the underlying mechanisms
involved in secondary SCI. Results obtained through in vitro
and in vivo experiments suggest that the Fas–FasL system also
Figure 10. Effects of olprinone on intrinsic apoptotic pathway. SCI caused, at 24 h, an increase in Bax expression as evidenced by Western
blot analysis (A). Olprinone treatment (0,2 mg/kg) reduced the degree of positive staining for Bax in the spinal cord (A). Moreover, a basal level of Bcl-
2 expression was detected in spinal cord from sham-operated mice (B). Twenty-four hours after SCI, Bcl-2 expression was significantly reduced in
spinal cord from SCI mice. Olprinone treatments (0,2 mg/kg, 1 h and 6 h after SCI induction) significantly reduced the SCI-induced inhibition of Bcl-2
expression (B).
doi:10.1371/journal.pone.0012170.g010
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further supported by in vitro experiments showing that Fas was
capable of transducing apoptotic signals through the mitochon-
drial apoptotic pathway in neuronal and glial cells after traumatic
injury or exposure to the Fas-activating antibody [68]. Strategies
to inhibit Fas–FasL interaction may be useful neuroprotective
approaches for reducing apoptosis after SCI.
The balance of pro-apoptotic (Bax) and anti-apoptotic (Bcl-2
and Bcl-xL) proteins modulates intrinsic apoptotic cell death, thus
determining the relative sensitivity of cells to apoptotic stimuli.
The anti-apoptotic proteins Bcl-2 and Bcl-xL also play an
important role in controlling programmed cell death by either
promoting or preventing the release of pro-apoptotic mitochon-
drial proteins.
Various studies have postulated that preserving Bax, a pro-
apoptotic gene, plays an important role in developmental cell
death [69] and in CNS injury [70]. Similarly, it has been shown
that the administration of Bcl-xL fusion protein (Bcl-xL FP), (Bcl-2
is the most expressed antiapoptotic molecule in adult central
nervous system) into injured spinal cords significantly increased
neuronal survival, suggesting that SCI-induced changes in Bcl-xL
contribute considerably to neuronal death. Based on these
evidences, we have identified in SCI proapoptotic transcriptional
changes, including upregulation of proapoptotic Bax and down
regulation of antiapoptotic Bcl-2, by immunohystochemical
staining. We report in the present study that the pharmacological
inhibition of PDE III pathway by olprinone in experimental model
of spinal cord trauma documents features of apoptotic cell death
after SCI, suggesting that protection from apoptosis may be a
prerequisite for regenerative approaches to SCI. However is not
possible to exclude that anti- apoptotic effect observed after
olprinone treatment it may be partially dependent on the
attenuation of the inflammatory-induced damage. Further studies
are needed in order to clarify these mechanisms.
Figure 11. Effects of olprinone on apoptotic proteins. Staining for Bax expression was absent in Sham group (A). Twenty-four hours after SCI,
spinal cord tissue from injured-animals showed a positive staining for Bax (B). Olprinone treatments (0,2 mg/kg) significantly reduced the SCI-induced
Bax (C). On the contrary, positive staining for Bcl-2 was observed in the spinal cord tissues from sham-operated mice (D) while the staining was
significantly reduced in SCI mice (E). Olprinone treatment attenuated the loss of positive staining for Bcl-2 in the spinal cord from SCI- subjected mice
(F). Data are expressed as% of total tissue area.
doi:10.1371/journal.pone.0012170.g011
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of neural cell damage. However, it has recently been suggested
that inhibiting the products of S100b can be a potential
therapeutic target in acute stroke patients [71]. This indicates
that S100b itself might exacerbate ischemic neuronal damage, a
possible mechanism of which might be propagation of neuroin-
flammation through astrocytic gap junction and also enhancement
of NO production in the ischemic brain [72,73]. In the present
study, significantly lower levels of nitrotyrosine and S100b were
detected in olprinone-treated animals. We think that the
production of S100b is affected by IL-1 signals in a direct fashion
and also by an unknown secondary mechanism under the complex
cytokine network. The reduction of these parameters resulted in
the suppression of the cytokine cycles and attenuation of the
continuous oxidative stress.
Although our analysis was focused on olprinone as monother-
apy for SCI, its low toxicity suggests that it may be added as
adjunctive therapy to methylprednisone, minocycline, or other
anti-inflammatory drugs as well. Such combination therapy may
well enhance the possibility of optimal recovery of function
following traumatic injury to the human spinal cord.
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